Arcturus Up 26% After Hours on CSL Seqirus Vaccine Collaboration
November 01 2022 - 7:27PM
Dow Jones News
By Josh Beckerman
Arcturus Therapeutics Holdings Inc. shares rose 26% to $23.10
after hours as the company announced a vaccine collaboration with
CSL Ltd.'s CSL Seqirus.
Arcturus will receive $200 million upfront and is eligible to
receive over $1.3 billion in development milestones and more than
$3 billion in commercial milestones.
In addition, it is eligible to receive a 40% net profit share
for Covid-19 vaccine products and up to double-digit royalties for
certain other vaccines.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 01, 2022 19:12 ET (23:12 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
CSL (ASX:CSL)
Historical Stock Chart
From Oct 2024 to Nov 2024
CSL (ASX:CSL)
Historical Stock Chart
From Nov 2023 to Nov 2024
